Journal of Inherited Metabolic Disease

, Volume 31, Issue 3, pp 319–336 | Cite as

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

  • T. M. Cox
  • J. M. F. G. Aerts
  • N. Belmatoug
  • M. D. Cappellini
  • S. vom Dahl
  • J. Goldblatt
  • G. A. Grabowski
  • C. E. M. Hollak
  • P. Hwu
  • M. Maas
  • A. M. Martins
  • P. K. Mistry
  • G. M. Pastores
  • A. Tylki-Szymanska
  • J. Yee
  • N. Weinreb


Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.


Bone Mineral Density Enzyme Replacement Therapy Gauche Disease Bone Marrow Infiltration Miglustat 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The Second International Gaucher Disease Management Board is an independent body supported by an educational grant by Genzyme Corporation, Cambridge, MA. This publication was supported by an unrestricted educational grant from Genzyme Corporation, Cambridge, MA. Editorial support was provided by Conscience Creative LLP, Leatherhead, UK. The opinions or views expressed in this paper are those of the authors and do not necessarily reflect the opinions or recommendations of Genzyme Corporation.


  1. Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin Haematol 10(4): 691–709.PubMedCrossRefGoogle Scholar
  2. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278(42): 40911–40916.PubMedCrossRefGoogle Scholar
  3. Altarescu G, Schiffmann R, Parker CC, et al (2000) Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26(4): 285–290.PubMedCrossRefGoogle Scholar
  4. Amato D, Stachiw T, Clarke JT, et al (2004) Gaucher disease: variability in phenotype among siblings. J Inherit Metab Dis 27(5): 659–669.PubMedCrossRefGoogle Scholar
  5. Amory JK, Muller CH, Page ST, et al (2007) Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod 22(3): 702–707.PubMedCrossRefGoogle Scholar
  6. Andersson HC, Charrow J, Kaplan P, et al (2005) International Collaborative Gaucher Group U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7(2): 105–110.PubMedCrossRefGoogle Scholar
  7. Aporta Rodriguez R, Escobar Vedia JL, Navarro Castro AM, et al (1998) Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica 83(9): 852–853.PubMedGoogle Scholar
  8. Ashkenazi A, Zaizov R, Matoth Y (1986) Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr 145(1–2): 138–141.PubMedCrossRefGoogle Scholar
  9. Ayhan A, Tuncer ZS, Simsek H (1996) Gaucher’s disease and pregnancy. Eur J Obstet Gynecol Reprod Biol 66(1): 69–70.PubMedCrossRefGoogle Scholar
  10. Babyn PS, Ranson M, McCarville ME (1998) Normal bone marrow: signal characteristics and fatty conversion. Magn Reson Imaging Clin N Am 6(3): 473–495.PubMedGoogle Scholar
  11. Bamias A, Kastritis E, Bamia C, et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34): 8580–8587.PubMedCrossRefGoogle Scholar
  12. Barton NW, Brady RO, Dambrosia JM, et al (1991). Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324(21): 1464–1470.PubMedGoogle Scholar
  13. Bembi B, Zanatta M, Carrozzi M, et al (1994) Enzyme replacement treatment in type 1 and type 3 Gaucher’s disease. Lancet 344(8938): 1679–1682.PubMedCrossRefGoogle Scholar
  14. Bembi B, Ciana G, Mengel E, et al (2002) Bone complications in children with Gaucher disease. Br J Radiol 75(Supplement 1): A37–44.PubMedGoogle Scholar
  15. Berridge MJ, Bootman MD, Lipp P (1998) Calcium—a life and death signal. Nature 395(6703): 645–648.PubMedCrossRefGoogle Scholar
  16. Beutler E, Grabowski GA (2001). Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.Google Scholar
  17. Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35(3): 355–364.PubMedCrossRefGoogle Scholar
  18. Boot RG, Verhoek M, de Fost M, et al (2004). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103(1): 33–39.PubMedCrossRefGoogle Scholar
  19. Boot RG, Verhoek M, Langeveld M, et al (2006) CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis 29(4): 564–571.PubMedCrossRefGoogle Scholar
  20. Boven LA, van Meurs M, Boot RG, et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122(3): 359–369.PubMedCrossRefGoogle Scholar
  21. Cabrera-Salazar MA, O’Rourke E, Henderson N, et al (2004) Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 344(1–2): 101–107.PubMedCrossRefGoogle Scholar
  22. Capablo JL, Saenz de Cabezon A, Fraile J, et al (2008) Neurological evaluation of Gaucher disease patients diagnosed as type 1. J Neurol Neurosurg Psychiatry 79(2): 219–222. (Epub 2007 Aug 6).PubMedCrossRefGoogle Scholar
  23. Charrow J, Andersson HC, Kaplan P, et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160(18): 2835–2843.PubMedCrossRefGoogle Scholar
  24. Charrow J, Andersson HC, Kaplan P, et al (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144(1): 112–120.PubMedCrossRefGoogle Scholar
  25. Charrow J, Dulisse B, Grabowski GA, et al (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71(3): 205–211.PubMedCrossRefGoogle Scholar
  26. Chérin P, Sedel F, Mignot C, et al (2006) Neurological manifestations of type 1 Gaucher’s disease: Is a revision of disease classification needed? [in French]. Rev Neurol (Paris) 162(11): 1076–1083.Google Scholar
  27. Ciana G, Cuttini M, Bembi B (1997) Short-term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement. N Engl J Med 337(10): 712.PubMedCrossRefGoogle Scholar
  28. Ciana G, Martini C, Leopaldi A, et al (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72(3): 185–189.PubMedCrossRefGoogle Scholar
  29. Ciana G, Addobbati R, Tamaro G, et al (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28: 723–732.PubMedCrossRefGoogle Scholar
  30. Clarkson CP, Magann EF, Siddique SA, et al (1998) Hematological complications of Gaucher’s disease in pregnancy. Mil Med 163(7): 499–501.PubMedGoogle Scholar
  31. Cleary JE, Burke WM, Baxi LV (2001) Pregnancy after avascular necrosis of the femur complicating Gaucher’s disease. Am J Obstet Gynecol 184(2): 233–234.PubMedCrossRefGoogle Scholar
  32. Cox TM (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24(Supplement 2): 106–121; discussion 87–88.PubMedGoogle Scholar
  33. Cox TM, Schofield JP (1997) Gaucher’s disease: clinical features and natural history. Baillieres Clin Haematology 10(4): 657–689.CrossRefGoogle Scholar
  34. Cox TM, Hollak C, et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214): 1481–1485.PubMedCrossRefGoogle Scholar
  35. Cox TM, Aerts JM, Andria G, et al (2003) Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26(6): 513–526.PubMedCrossRefGoogle Scholar
  36. Davies JM, Barnes R, Milligan D (2002) British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2(5): 440–443.PubMedGoogle Scholar
  37. Deegan PB, Cox TM (2005) Clinical evaluation of biomarkers in Gaucher disease. Acta Paediatr Supplement 94(447): 47–50; discussion 37–38.CrossRefGoogle Scholar
  38. Deegan PB, Moran MT, McFarlane I, et al (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35: 259–267.PubMedCrossRefGoogle Scholar
  39. de Fost M. Aerts JMFG, Hollak CEM (2003) Gaucher disease: from fundamental research to effective therapeutic interventions. Neth J Med 61(1): 3–8.PubMedGoogle Scholar
  40. de Fost M, Hollak CE, Groener JE, et al (2006a) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a2-center retrospective analysis. Blood 108(3): 830–835.PubMedCrossRefGoogle Scholar
  41. de Fost M, Vom Dahl S, Weverling GJ, et al (2006b) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36(1): 53–58.PubMedCrossRefGoogle Scholar
  42. Diamond LK (1969) Splenectomy in childhood and the hazard of overwhelming infection. Pediatrics 43(5): 886–889.PubMedGoogle Scholar
  43. Dimitriou E, Verhoek M, Altun S, et al (2005) Elevated plasma chemokine CCL18/PARC in beta-thalassemia. Blood Cells Mol Dis 35(3): 328–331.PubMedCrossRefGoogle Scholar
  44. Ein SH, Shandling B, Simpson JS, et al (1977) The morbidity and mortality of splenectomy in childhood. Ann Surg 185(3): 307–310.PubMedCrossRefGoogle Scholar
  45. El-Beshlawy A, Ragab L, Youssry I, et al (2006) Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29(1): 92–98.PubMedCrossRefGoogle Scholar
  46. Elstein D, Granovsky-Grisaru S, Rabinowitz R, et al (1997) Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 177(6): 1509–1512.PubMedCrossRefGoogle Scholar
  47. Elstein D, Klutstein MW, Lahad A, et al (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet 351(9115): 1544–6.PubMedCrossRefGoogle Scholar
  48. Elstein D, Hollak C, Aerts JM, et al (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27(6): 757–766.CrossRefGoogle Scholar
  49. Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al (2004) Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 190(2): 435–441.CrossRefGoogle Scholar
  50. EMEA (European Agency for the Evaluation of Medicinal Products) (2002). Zavesca prescribing data. (Accessed 07/09/07).
  51. EMEA (European Agency for the Evaluation of Medicinal Products). (2005) Cerezyme prescribing data. (Accessed 07/09/07).
  52. Esplin J, Greenspoon JS, Cheng E, et al (1993) Alglucerase infusions in pregnant type 1 Gaucher patients [Abstract]. Blood 82: 509A.Google Scholar
  53. FDA (Food and Drug Administration) (2002) Cerezyme prescribing data. (Accessed 07/09/07).
  54. FDA (Food and Drug Adminstration) (2003): Zavesca prescribing data. (Accessed 07/09/07).
  55. Finkelstein R, Nachum Z, Reissman P, et al (1992) Anaerobic osteomyelitis in patients with Gaucher’s disease. Clin Infect Dis 15(5): 771–773.PubMedGoogle Scholar
  56. Fiore CE, Barone R, Pennisi P, et al (2002) Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 20(1): 34–38PubMedCrossRefGoogle Scholar
  57. Fleshner PR, Aufses AH Jr, Grabowski GA, et al (1991) A 27-year experience with splenectomy for Gaucher’s disease. Am J Surg 161(1): 69–75.PubMedCrossRefGoogle Scholar
  58. Futerman AH (2006). Cellular pathology in Gaucher disease. In Futerman AH and Zimran A, eds. Gaucher Disease. Boca Raton, FL: CRC/Taylor and Francis, 97–108.Google Scholar
  59. Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5(7): 554–565.PubMedCrossRefGoogle Scholar
  60. Goldblatt J, Beighton P (1985) Obstetric aspects of Gaucher disease. Br J Obstet Gynaecol 92(2): 145–149.PubMedGoogle Scholar
  61. Goldblatt J, Sacks S, Beighton P (1978) The orthopedic aspects of Gaucher disease. Clin Orthop Relat Res (137): 208–214.Google Scholar
  62. Grabowski GA (1997) Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1(1): 5–12.PubMedGoogle Scholar
  63. Grabowski GA, Kolodny EH, Weinreb NJ, et al (2006) Gaucher disease: phenotype and genetic variation. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, accessed via
  64. Grace ME, Balwani M, Nazarenko I, et al (2007) Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 28(9): 866–873.PubMedCrossRefGoogle Scholar
  65. Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, et al (1995) Gynecologic and obstetric aspects of Gaucher’s disease: a survey of 53 patients. Am J Obstet Gynecol 172(4 Pt 1): 1284–1290.PubMedCrossRefGoogle Scholar
  66. Guffon N (2006) Gaucher disease and chitotriosidase [in French]. Rev Med Interne 27(Supplement 1): S26–29.PubMedGoogle Scholar
  67. Hall MB, Brown RW, Baughman RA (1985). Gaucher’s diseaseaffecting the mandible. J Oral Maxillofac Surg 43(3): 210–213.PubMedCrossRefGoogle Scholar
  68. Hermann G, Goldblatt J, Levy RN, et al (1986) Gaucher’s disease type 1: assessment of bone involvement by CT and scintigraphy. AJR Am J Roentgenol 147(5): 943–948.PubMedGoogle Scholar
  69. Hoeper MM, Niedermeyer J, Hoffmeyer F, et al (1999) Pulmonary hypertension after splenectomy? Ann Intern Med 130(6): 506–509.PubMedGoogle Scholar
  70. Hollak CE, van Weely S, van Oers MH, et al (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3): 1288–1292.PubMedCrossRefGoogle Scholar
  71. Hollak CE, Aerts JM, Goudsmit R, et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher’s disease. Lancet 345(8963): 1474–1478.PubMedCrossRefGoogle Scholar
  72. Hollak CE, Levi M, Berends F, et al (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96(3): 470–476.PubMedCrossRefGoogle Scholar
  73. Hollak CE, Maas M, Akkerman E, et al (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27(6): 1005–1012.PubMedCrossRefGoogle Scholar
  74. Holtkamp W, Kuhn W, Kunze E, et al (1998) Gaucher disease and pregnancy [in German]. Z Geburtshilfe Perinatol 192(6): 278–281.Google Scholar
  75. Houlton MC, Jackson MB (1978). Gaucher’s disease and pregnancy. Obstet Gynecol 51(5): 619–620.PubMedCrossRefGoogle Scholar
  76. Hruska KS, Goker-Alpan O, Sidransky E (2006) Gaucher disease and the synucleinopathies. J Biomed Biotechnol (3): 78549.Google Scholar
  77. Hughes D, Cappellini MD, Berger M et al (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138(6): 676–686.PubMedCrossRefGoogle Scholar
  78. Ida H, Rennert OM, Kato S, et al (1999) Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 22(1): 63–73.PubMedCrossRefGoogle Scholar
  79. Ioscovich A, Elstein Y, Halpern S, et al (2004) Anesthesia for obstetric patients with Gaucher disease: survey and review. Int J Obstet Anesth 13(4): 244–250.PubMedCrossRefGoogle Scholar
  80. Jimenez Saenz M, Romero Castro R, Carrasco Diaz F, et al (1991) Gaucher’s disease type I, anticoagulant factor and pregnancy [in Spanish]. An Med Interna 8(6): 294–295.PubMedGoogle Scholar
  81. Johnson LA, Hoppel BE, Gerard EL, et al (1992). Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182(2): 451–455.PubMedGoogle Scholar
  82. Junod AF, Carrel JP, Richter M, et al (2005) Osteonecrosis of the jaws and bisphosphonates [in French]. Rev Med Suisse 1(39): 2537–2540, 2542–2543.PubMedGoogle Scholar
  83. Kaloterakis A, Filiotou A, Koskinas J, et al (1999) Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. J Intern Med 246(6): 587–590.PubMedCrossRefGoogle Scholar
  84. Kaplan P, Andersson HC, Kacena KA, Yee JD (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006 160(6): 603–608.CrossRefGoogle Scholar
  85. Kelsey H, Christopoulos C, Gray AA, et al (1994) Acquired pseudo-pseudo Bernard–Soulier syndrome complicating Gaucher’s disease. J Clin Pathol 47(2): 162–165.PubMedCrossRefGoogle Scholar
  86. Kinoshita H, Tamaki T, Hashimoto T, et al (1998) Factors influencing lumbar spine bone mineral density assessment by dual-energy X-ray absorptiometry: comparison with lumbar spinal radiogram. J Orthop Sci 3(1): 3–9.PubMedCrossRefGoogle Scholar
  87. Kolodny EH, Ullman MD, Mankin HJ, et al (1982) Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res 95: 33–65.PubMedGoogle Scholar
  88. Koprivica V, Stone DL, Park JK, et al (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66(6): 1777–1786.PubMedCrossRefGoogle Scholar
  89. Kortotian E, Schwarz A, Pelled D, et al (1999) Elevation of intracellular glucosylceramide levels results in increse in endoplasmic reticulum density and in functional calcium stores in cultured neurones. J Biol Chem 274: 21673–21678.CrossRefGoogle Scholar
  90. Krasnewich D, Dietrich K, Bauer L, et al (1998) Splenectomy in Gaucher disease: new management dilemmas. Blood 91(8): 3085–3087.PubMedGoogle Scholar
  91. Kyaw MH, Holmes EM, Toolis F, et al (2006) Evaluation of severe infection and survival after splenectomy. Am J Med 119(3): 276.e1–7.CrossRefGoogle Scholar
  92. Kyllerman M, Conradi N, Mansson JE, et al (1990) Rapidly progressive type III Gaucher disease: deterioration following partial splenectomy. Acta Paediatr Scand 79(4): 448–453.PubMedCrossRefGoogle Scholar
  93. Lachmann RH, Wight DG, Lomas DJ, et al (2000) Massive hepatic fibrosis in Gaucher’s disease: clinico-pathological and radiological features. QJM 93(4): 237–244.PubMedCrossRefGoogle Scholar
  94. Lachmann RH, Grant IR, Halsall D, et al (2004) Twin pairs showing discordance of phenotype in adult Gaucher’s disease. QJM 97(4): 199–204.PubMedCrossRefGoogle Scholar
  95. Laine F, Guyader D, Turlin B, et al (1996) Hyper-ferritinemia and Gaucher disease [in French]. Gastroenterol Clin Biol 20(5): 512–513.PubMedGoogle Scholar
  96. Landyshev IuS, Tochilin VI (1989) Gaucher’s disease and pregnancy [in Russian]. Ter Arkh 61(10): 81–3.PubMedGoogle Scholar
  97. Lebel E, Dweck A, Foldes AJ, et al (2004) Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 22(6): 597–601.PubMedCrossRefGoogle Scholar
  98. Lee RE (1982) The pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowski GA, eds. Gaucher Disease: A Century of Delineation and Research, New York: Liss, 177–217.Google Scholar
  99. Lester TJ, Grabowski GA, Goldblatt J, et al (1984) Immune thrombocytopenia and Gaucher’s disease. Am J Med 77(3): 569–571.PubMedCrossRefGoogle Scholar
  100. Liu G, Peacock M, Eilam O, et al (1997) Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women.Osteoporos Int 7(6): 564–569.PubMedCrossRefGoogle Scholar
  101. Maas M, Hollak CE, Akkerman EM, et al (2002) Quantification of skeletal involvement in adults with type I Gaucher’s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179(4): 961–965.PubMedGoogle Scholar
  102. Maas M, van Kuijk C, Stoker J, et al (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging—initial experience. Radiology 229(2): 554–561.PubMedCrossRefGoogle Scholar
  103. Maas M, Hangartner T, Mariani G, et al (2008) Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol 37(3): 185–188.PubMedCrossRefGoogle Scholar
  104. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al (2000). The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 23(1): 77–82.PubMedCrossRefGoogle Scholar
  105. Magal I, Lebel E, Altarescu G, et al (2006) Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. Br J Haematol 133(1): 93–97.PubMedGoogle Scholar
  106. Margalit M, Ash N, Zimran A, et al (2002) Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher’s disease. Postgrad Med J 78(923): 564–565.PubMedCrossRefGoogle Scholar
  107. Mariani G, Filocamo M, Giona F, et al (2003) Severity of bone marrow involvement in patients with Gaucher’s disease evaluated by scintigraphy with99mTc-Sestamibi. J Nucl Med 44(8): 1253–1262.PubMedGoogle Scholar
  108. Marini JC (2003) Do bisphosphonates make children’s bones better or brittle? N Engl J Med 349(5): 423–426.PubMedCrossRefGoogle Scholar
  109. Marx RE, Sawatari Y, Fortin M, et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11): 1567–1575.PubMedCrossRefGoogle Scholar
  110. Mazor M, Wiznitzer A, Pinku A, et al (1986) Gaucher’s disease in pregnancy associated with portal hypertension. Am J Obstet Gynecol 154(5): 1119–1120.PubMedGoogle Scholar
  111. McClung MR (2006). Do current management strategies and guidelines adequately address fracture risk? Bone 38(2 Supplement 2): 13–17.CrossRefGoogle Scholar
  112. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281(3): 249–254.PubMedCrossRefGoogle Scholar
  113. Miller SP, Zirzow GC, Doppelt SH, et al (1996) Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 127(4): 353–358.PubMedCrossRefGoogle Scholar
  114. Mistry PK, Wraight EP, Cox TM (1996) Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher’s disease. Lancet 348(9041): 1555–1559.PubMedCrossRefGoogle Scholar
  115. Mistry PK, Sirrs S, Chan A, et al (2002) Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77(1–2): 91–98.PubMedCrossRefGoogle Scholar
  116. Moran MT, Schofield JP, Hayman AR et al (2000). Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96(5): 1969–1978.PubMedGoogle Scholar
  117. Najm SA, Lysitsa S, Carrel JP, et al (2005) Bisphosphonates-related jaw osteonecrosis [in French]. Presse Med 34(15): 1073–1077.PubMedCrossRefGoogle Scholar
  118. Ostlere SJ, Gold RH (1991) Osteoporosis and bone density measurement methods. Clin Orthop Relat Res: (271): 149–163.Google Scholar
  119. Pastores GM, Wallenstein S, Desnick RJ, et al (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11(11): 1801–1807.PubMedCrossRefGoogle Scholar
  120. Pastores GM, Weinreb NJ, Aerts H, et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Supplement 5): 4–14.PubMedCrossRefGoogle Scholar
  121. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27(8): 1215–1227.PubMedCrossRefGoogle Scholar
  122. Patlas M, Hadas-Halpern I, Abrahamov A, et al (2002) Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 3(1): 17–20.PubMedCrossRefGoogle Scholar
  123. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, et al (2005). Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 18(1): 83–88.PubMedCrossRefGoogle Scholar
  124. Pinto R, Caseiro C, Lemos M, et al (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12(2): 87–92.PubMedCrossRefGoogle Scholar
  125. Poll LW, Koch JA, vom Dahl S, et al (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 30(9): 496–503.PubMedCrossRefGoogle Scholar
  126. Poorthuis BJ, Wevers RA, Kleijer WJ, et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105(1–2): 151–156.PubMedGoogle Scholar
  127. Price VE, Dutta S, Blanchette VS, et al (2006) The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 46(5): 597–603.PubMedCrossRefGoogle Scholar
  128. Pye SR, Reid DM, Lunt M, et al (2007) Lumbar disc degeneration: association between osteophytes, end-plate sclerosis and disc space narrowing. Ann Rheum Dis 66(3): 330–333.PubMedCrossRefGoogle Scholar
  129. Robertson PL, Maas M, Goldblatt J (2007). Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher’s disease using the bone marrow burden score. AJR Am J Roentgenol 188(6): 1521–1528.PubMedCrossRefGoogle Scholar
  130. Rodrigue SW, Rosenthal DI, Barton NW, et al (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher’s disease. Clin Orthop Relat Res (362): 201–207.Google Scholar
  131. Rose JS, Grabowski GA, Barnett SH, et al (1982) Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease. AJR Am J Roentgenol 139(6): 1202–1204.PubMedGoogle Scholar
  132. Rosenbloom BE, Weinreb NJ, Zimran A, et al (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105(12): 4569–4572.PubMedCrossRefGoogle Scholar
  133. Rosenthal DI, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–637.PubMedGoogle Scholar
  134. Rudzki Z, Okon K, Machaczka M, et al (2003) Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease—a histological study. Eur J Haematol 70(5): 273–281.PubMedCrossRefGoogle Scholar
  135. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5): 527–534.PubMedCrossRefGoogle Scholar
  136. Salky B, Kreel I, Gelernt I, et al (1979) Splenectomy for Gaucher’s disease. Ann Surg 190(5): 592–594.PubMedCrossRefGoogle Scholar
  137. Schiffmann R, Mankin H, Dambrosia JM, et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28(2): 288–296.PubMedCrossRefGoogle Scholar
  138. Schueler UH, Kolter T, Kaneski CR, et al (2003) Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis 14(3): 595–601.PubMedCrossRefGoogle Scholar
  139. Sherer Y, Dulitzki M, Levy Y, et al (2002) Successful pregnancy outcome in a patient with Gaucher’s disease and antiphospholipid syndrome. Ann Hematol 81(3): 161–163.PubMedCrossRefGoogle Scholar
  140. Shiloni E, Bitran D, Rachmilewitz E, et al (1983) The role of splenectomy in Gaucher disease. Arch Surg 118(8): 929–932.PubMedGoogle Scholar
  141. Shiran A, Brenner B, Laor A, et al (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72(1): 219–224.PubMedCrossRefGoogle Scholar
  142. Sly WS, Kaplan A, Achord DT, et al (1978) Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 23: 547–551.PubMedGoogle Scholar
  143. Suganuma R, Walden CM, Butters TD, et al (2005) Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod 72(4): 805–813.PubMedCrossRefGoogle Scholar
  144. Tordjeman N, Monnier JC, Hautefeuille P, et al (1991) Gaucher’s disease and pregnancy [in French]. J Gynecol Obstet Biol Reprod (Paris) 20(6): 835–840.Google Scholar
  145. Torloni MR, Franco K, Sass N (2002) Gaucher’s disease with myocardial involvement in pregnancy. Sao Paulo Med J 120(3): 90–92.PubMedCrossRefGoogle Scholar
  146. van Breemen MJ, de Fost M, Voerman JS, et al (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772(7): 788–796.PubMedGoogle Scholar
  147. van der Spoel AC, Jeyakumar M, Butters TD, et al (2002) Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A 99(26): 17173–17178.PubMedCrossRefGoogle Scholar
  148. Van Poznak C (2006) The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest 24(1): 110–112.PubMedCrossRefGoogle Scholar
  149. Vellodi A, Foo Y, Cole TJ (2005) Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis 28(4): 585–592.PubMedCrossRefGoogle Scholar
  150. vom Dahl S, Poll L, Di Rocco M, et al (2006) Evidence based recommendations for monitoring bone disease and the response to therapy in Gaucher patients. Curr Med Res Opin 22(6): 1045–1064.CrossRefGoogle Scholar
  151. Weinreb NJ, Charrow J, Andersson HC, et al (2002). Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113(2): 112–119.PubMedCrossRefGoogle Scholar
  152. Weinreb NJ, Aggio MC, Andersson HC, et al (2004) International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41(4 Supplement 5): 15–22. Erratum in: Semin Hematol 2000 42(3): 179.PubMedCrossRefGoogle Scholar
  153. Weinreb NJ, Barranger JA, Charrow J, et al (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80(3): 223–229.PubMedCrossRefGoogle Scholar
  154. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(Supplement 1): A2–12.PubMedGoogle Scholar
  155. Wenstrup RJ, Bailey L, Grabowski GA, et al (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104(5): 1253–1257.PubMedCrossRefGoogle Scholar
  156. Wenstrup RJ, Kacena KA, Kaplan P, et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22(1): 119–126.PubMedCrossRefGoogle Scholar
  157. Whyte MP (2006) The long and the short of bone therapy. N Engl J Med 354(8): 860–863.PubMedCrossRefGoogle Scholar
  158. Young E, Chatterton C, Vellodi A, et al (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis 20: 595–692.PubMedCrossRefGoogle Scholar
  159. Young KR, Payne MJ (1986) Reversible splenic enlargement associated with pregnancy in a patient with Gaucher’s disease. J R Army Med Corps 132(3): 157–158.PubMedGoogle Scholar
  160. Zarychanski R, Elphee E, Walton P, et al (2006) Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81(1): 73–75.PubMedCrossRefGoogle Scholar
  161. Zimran A, Kay A, Gelbart T, et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71(6): 337–353.CrossRefGoogle Scholar
  162. Zimran A, Liphshitz I, Barchana M, et al (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34(3): 197–200.PubMedCrossRefGoogle Scholar
  163. Zlotogora J, Sagi M, Zeigler M, et al (1989) Gaucher disease type I and pregnancy. Am J Med Genet 32(4): 475–477.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • T. M. Cox
    • 1
    • 17
  • J. M. F. G. Aerts
    • 2
  • N. Belmatoug
    • 3
  • M. D. Cappellini
    • 4
  • S. vom Dahl
    • 5
  • J. Goldblatt
    • 6
  • G. A. Grabowski
    • 7
  • C. E. M. Hollak
    • 8
  • P. Hwu
    • 9
  • M. Maas
    • 10
  • A. M. Martins
    • 11
  • P. K. Mistry
    • 12
  • G. M. Pastores
    • 13
  • A. Tylki-Szymanska
    • 14
  • J. Yee
    • 15
  • N. Weinreb
    • 16
  1. 1.Department of MedicineUniversity of Cambridge, Addenbrooke’s NHS Foundation Hospitals TrustCambridgeUK
  2. 2.Department of Medical Biochemistry, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  3. 3.Department of Internal Medicine, Hôpital BeaujonAssistance Publique-Hôpitaux de ParisParisFrance
  4. 4.Department of Internal Medicine, Policlinico Foundation IRCCSUniversity of MilanMilanItaly
  5. 5.Department of Internal MedicineSt Franziskus HospitalCologneGermany
  6. 6.Genetic Services of Western Australia, King Edward Memorial Hospital for Women, School of Paediatrics and Child HealthUniversity of WAPerthAustralia
  7. 7.Division of Human Genetics, MLC 4006Cincinnati Children’s Hospital Medical CenterCincinnatiUSA
  8. 8.Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  9. 9.Department of Pediatrics and Medical GeneticsNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiROC
  10. 10.Department of Radiology, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  11. 11.Reference Center in Inborn Errors of MetabolismFederal University of São Paulo (UNIFESP)São PauloBrazil
  12. 12.Yale University School of Medicine, Internal MedicineNew HavenUSA
  13. 13.Neurogenetics Unit, Departments of Neurology and PediatricsNYU School of MedicineNew YorkUSA
  14. 14.Department of Metabolic DiseasesThe Children’s Memorial Health InstituteWarsawPoland
  15. 15.Genzyme CorporationCambridgeUSA
  16. 16.University Research Foundation for Lysosomal Storage Diseases and Northwest Oncology Hematology Associates PACoral SpringsUSA
  17. 17.Department of MedicineUniversity of CambridgeCambridgeUK

Personalised recommendations